first week tirzepatide Weight Loss: What to Expect what to expect when starting

Disha Narang, an endocrinologist and the director of Obesity Medicine at Northwestern Lake Forest Hospital in Illinois, told The Post compounded semaglutide is not FDA approved and we dont have any data on long-term efficacy. Furthermore, she said Eli Lilly and Novo Nordisk, the makers of diabetes drugs tirzepatide and semaglutide, are going to be coming after a lot of these manufacturers that are making compounded substances. In a press release distributed last week, Novo Nordisk cited trademark issues and safety concerns and said it is taking steps to protect US patients from the unlawful marketing and sales of non-FDA approved counterfeit and compounded semaglutide products claiming to contain semaglutide, while reinforcing the responsible use of Novo Nordisks FDA-approved medicines. Novo Nordisk has commenced the filing of legal actions in the US against certain medical spas, weight loss or wellness clinics, and compounding pharmacies to cease and desist from false advertising, trademark infringement and/or unlawful sales of non-FDA approved compounded products claiming to contain semaglutide, said the release

Chemical Peels Chemical peels are another alternative available at top clinics like Cara clinic that offers exfoliation and skin lightening

Gastrointestinal Very common (10% or more): Gastrointestinal adverse reactions (up to 73%), nausea (up to 44%), vomiting (up to 36%), diarrhea (up to 30%), constipation (up to 24.2%), abdominal pain (up to 20%) Common (1% to 10%): Dyspepsia, abdominal distension, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease, gastritis, viral gastroenteritis, increased amylase, increased lipase, dry mouth, severe gastrointestinal adverse reactions, delayed gastric emptying Uncommon (0.1% to 1%): Acute pancreatitis, appendicitis Frequency not reported : Hemorrhoids, hiccups Postmarketing reports : Ileus, intestinal obstruction, severe constipation, hiccups, acute pancreatitis, necrotizing pancreatitis In clinical trials in adults using the subcutaneous injection for weight reduction, 73% of treated patients reported gastrointestinal adverse reactions, including severe reactions (4.1%)

Blood Sugar Control : It helps improve glycemic control in individuals with type 2 diabetes, often leading to additional benefits in weight management

Patients with pernicious anemia who face B12 absorption problems need alternative treatment approaches since their bodies need longer to react to therapeutic interventions